Prognostic value of programmed cell death ligand 1 expression in patients with intrahepatic cholangiocarcinoma: a meta-analysis

Programmed cell death ligand 1 (PD-L1) is highly expressed in intrahepatic cholangiocarcinoma (ICC) tissues. But there is still a dispute over the prognostic value of PD-L1 in patients with ICC. This study aimed to evaluate the prognostic value of PD-L1 expression in patients with ICC. We performed...

Full description

Saved in:
Bibliographic Details
Published inFrontiers in immunology Vol. 14; p. 1119168
Main Authors Xian, Feng, Ren, Dacheng, Bie, Jun, Xu, Guohui
Format Journal Article
LanguageEnglish
Published Switzerland Frontiers Media S.A 17.04.2023
Subjects
Online AccessGet full text

Cover

Loading…
Abstract Programmed cell death ligand 1 (PD-L1) is highly expressed in intrahepatic cholangiocarcinoma (ICC) tissues. But there is still a dispute over the prognostic value of PD-L1 in patients with ICC. This study aimed to evaluate the prognostic value of PD-L1 expression in patients with ICC. We performed a meta-analysis based on the Preferred Reporting Items for Systematic Reviews and Meta-Analyses Guidelines. We searched the literature from PubMed, Embase, Web of Science, and the Cochrane Library up to December 5, 2022. Hazard ratios (HR) and their 95% confidence intervals (95% CI) were calculated to analyze the overall survival (OS), recurrence-free survival (RFS), and time to relapse. The quality of the studies was assessed using the Newcastle-Ottawa scale. Publication bias was assessed using a funnel plot and Egger's test. Ten trials with 1944 cases were included in this meta-analysis. The results showed that the low-PD-L1 group had a statistically significant advantage in OS (HR, 1.57; 95% CI, 1.38-1.79, P <0.00001), RFS (HR, 1.62; 95% CI, 1.34-1.97, P <0.00001), and time to relapse (HR, 1.60; 95% CI, 1.25-2.05, P = 0.0002) compared with the high-PD-L1 group. High programmed cell death (PD1)levels, on the other hand, were correlated with poorer OS (HR, 1.96; 95% CI, 1.43-2.70; P <0.0001) and RFS (HR, 1.87; 95% CI, 1.21-2.91; P = 0.005). Multivariate analysis showed that PD-L1 could act as an independent predictor for OS (HR, 1.48; 95% CI, 1.14-1.91; P = 0.003) and RFS (HR, 1.74; 95% CI, 1.22-2.47; P = 0.002), and PD1 acted as an independent predictor for OS (HR, 1.66; 95% CI, 1.15-2.38; P = 0.006). This meta-analysis demonstrated that high PD-L1/PD1 expression is associated with poor survival in ICC. PD-L1/PD1 may be a valuable prognostic and predictive biomarker and potential therapeutic target in ICC. https://www.crd.york.ac.uk/PROSPERO/, identifier CRD42022380093.
AbstractList BackgroundProgrammed cell death ligand 1 (PD-L1) is highly expressed in intrahepatic cholangiocarcinoma (ICC) tissues. But there is still a dispute over the prognostic value of PD-L1 in patients with ICC. This study aimed to evaluate the prognostic value of PD-L1 expression in patients with ICC. MethodsWe performed a meta-analysis based on the Preferred Reporting Items for Systematic Reviews and Meta-Analyses Guidelines. We searched the literature from PubMed, Embase, Web of Science, and the Cochrane Library up to December 5, 2022. Hazard ratios (HR) and their 95% confidence intervals (95% CI) were calculated to analyze the overall survival (OS), recurrence-free survival (RFS), and time to relapse. The quality of the studies was assessed using the Newcastle-Ottawa scale. Publication bias was assessed using a funnel plot and Egger's test. ResultsTen trials with 1944 cases were included in this meta-analysis. The results showed that the low-PD-L1 group had a statistically significant advantage in OS (HR, 1.57; 95% CI, 1.38-1.79, P <0.00001), RFS (HR, 1.62; 95% CI, 1.34-1.97, P <0.00001), and time to relapse (HR, 1.60; 95% CI, 1.25-2.05, P = 0.0002) compared with the high-PD-L1 group. High programmed cell death (PD1)levels, on the other hand, were correlated with poorer OS (HR, 1.96; 95% CI, 1.43-2.70; P <0.0001) and RFS (HR, 1.87; 95% CI, 1.21-2.91; P = 0.005). Multivariate analysis showed that PD-L1 could act as an independent predictor for OS (HR, 1.48; 95% CI, 1.14-1.91; P = 0.003) and RFS (HR, 1.74; 95% CI, 1.22-2.47; P = 0.002), and PD1 acted as an independent predictor for OS (HR, 1.66; 95% CI, 1.15-2.38; P = 0.006). ConclusionThis meta-analysis demonstrated that high PD-L1/PD1 expression is associated with poor survival in ICC. PD-L1/PD1 may be a valuable prognostic and predictive biomarker and potential therapeutic target in ICC. Systematic review registrationhttps://www.crd.york.ac.uk/PROSPERO/, identifier CRD42022380093.
Background Programmed cell death ligand 1 (PD-L1) is highly expressed in intrahepatic cholangiocarcinoma (ICC) tissues. But there is still a dispute over the prognostic value of PD-L1 in patients with ICC. This study aimed to evaluate the prognostic value of PD-L1 expression in patients with ICC. Methods We performed a meta-analysis based on the Preferred Reporting Items for Systematic Reviews and Meta-Analyses Guidelines. We searched the literature from PubMed, Embase, Web of Science, and the Cochrane Library up to December 5, 2022. Hazard ratios (HR) and their 95% confidence intervals (95% CI) were calculated to analyze the overall survival (OS), recurrence-free survival (RFS), and time to relapse. The quality of the studies was assessed using the Newcastle-Ottawa scale. Publication bias was assessed using a funnel plot and Egger’s test. Results Ten trials with 1944 cases were included in this meta-analysis. The results showed that the low-PD-L1 group had a statistically significant advantage in OS (HR, 1.57; 95% CI, 1.38–1.79, P <0.00001), RFS (HR, 1.62; 95% CI, 1.34–1.97, P <0.00001), and time to relapse (HR, 1.60; 95% CI, 1.25–2.05, P = 0.0002) compared with the high-PD-L1 group. High programmed cell death (PD1)levels, on the other hand, were correlated with poorer OS (HR, 1.96; 95% CI, 1.43–2.70; P <0.0001) and RFS (HR, 1.87; 95% CI, 1.21–2.91; P = 0.005). Multivariate analysis showed that PD-L1 could act as an independent predictor for OS (HR, 1.48; 95% CI, 1.14–1.91; P = 0.003) and RFS (HR, 1.74; 95% CI, 1.22–2.47; P = 0.002), and PD1 acted as an independent predictor for OS (HR, 1.66; 95% CI, 1.15–2.38; P = 0.006). Conclusion This meta-analysis demonstrated that high PD-L1/PD1 expression is associated with poor survival in ICC. PD-L1/PD1 may be a valuable prognostic and predictive biomarker and potential therapeutic target in ICC. Systematic review registration https://www.crd.york.ac.uk/PROSPERO/ , identifier CRD42022380093.
Programmed cell death ligand 1 (PD-L1) is highly expressed in intrahepatic cholangiocarcinoma (ICC) tissues. But there is still a dispute over the prognostic value of PD-L1 in patients with ICC. This study aimed to evaluate the prognostic value of PD-L1 expression in patients with ICC. We performed a meta-analysis based on the Preferred Reporting Items for Systematic Reviews and Meta-Analyses Guidelines. We searched the literature from PubMed, Embase, Web of Science, and the Cochrane Library up to December 5, 2022. Hazard ratios (HR) and their 95% confidence intervals (95% CI) were calculated to analyze the overall survival (OS), recurrence-free survival (RFS), and time to relapse. The quality of the studies was assessed using the Newcastle-Ottawa scale. Publication bias was assessed using a funnel plot and Egger's test. Ten trials with 1944 cases were included in this meta-analysis. The results showed that the low-PD-L1 group had a statistically significant advantage in OS (HR, 1.57; 95% CI, 1.38-1.79, P <0.00001), RFS (HR, 1.62; 95% CI, 1.34-1.97, P <0.00001), and time to relapse (HR, 1.60; 95% CI, 1.25-2.05, P = 0.0002) compared with the high-PD-L1 group. High programmed cell death (PD1)levels, on the other hand, were correlated with poorer OS (HR, 1.96; 95% CI, 1.43-2.70; P <0.0001) and RFS (HR, 1.87; 95% CI, 1.21-2.91; P = 0.005). Multivariate analysis showed that PD-L1 could act as an independent predictor for OS (HR, 1.48; 95% CI, 1.14-1.91; P = 0.003) and RFS (HR, 1.74; 95% CI, 1.22-2.47; P = 0.002), and PD1 acted as an independent predictor for OS (HR, 1.66; 95% CI, 1.15-2.38; P = 0.006). This meta-analysis demonstrated that high PD-L1/PD1 expression is associated with poor survival in ICC. PD-L1/PD1 may be a valuable prognostic and predictive biomarker and potential therapeutic target in ICC. https://www.crd.york.ac.uk/PROSPERO/, identifier CRD42022380093.
Author Bie, Jun
Xu, Guohui
Xian, Feng
Ren, Dacheng
AuthorAffiliation 3 Department of Interventional Radiology, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, Affiliated Cancer Hospital of University of Electronic Science and Technology of China , Chengdu , China
1 School of Medicine, University of Electronic Science and Technology of China , Chengdu , China
2 Department of Oncology, Nanchong Central Hospital, the Second Clinical Medical College, North Sichuan Medical College , Nanchong , China
AuthorAffiliation_xml – name: 1 School of Medicine, University of Electronic Science and Technology of China , Chengdu , China
– name: 2 Department of Oncology, Nanchong Central Hospital, the Second Clinical Medical College, North Sichuan Medical College , Nanchong , China
– name: 3 Department of Interventional Radiology, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, Affiliated Cancer Hospital of University of Electronic Science and Technology of China , Chengdu , China
Author_xml – sequence: 1
  givenname: Feng
  surname: Xian
  fullname: Xian, Feng
  organization: Department of Oncology, Nanchong Central Hospital, the Second Clinical Medical College, North Sichuan Medical College, Nanchong, China
– sequence: 2
  givenname: Dacheng
  surname: Ren
  fullname: Ren, Dacheng
  organization: Department of Oncology, Nanchong Central Hospital, the Second Clinical Medical College, North Sichuan Medical College, Nanchong, China
– sequence: 3
  givenname: Jun
  surname: Bie
  fullname: Bie, Jun
  organization: Department of Oncology, Nanchong Central Hospital, the Second Clinical Medical College, North Sichuan Medical College, Nanchong, China
– sequence: 4
  givenname: Guohui
  surname: Xu
  fullname: Xu, Guohui
  organization: Department of Interventional Radiology, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, Affiliated Cancer Hospital of University of Electronic Science and Technology of China, Chengdu, China
BackLink https://www.ncbi.nlm.nih.gov/pubmed/37138876$$D View this record in MEDLINE/PubMed
BookMark eNpVkk1v3CAQhq0qVZOm-QM9VBx78RYYbKCXqor6ESlSe2jPaBaDl8gGF7xpc-pfr53dRgkX0MvMM8PwvqxOYoquql4zugFQ-p0P47jfcMphwxjTrFXPqjPWtqIGzsXJo_NpdVHKDV2W0ADQvKhOQTJQSrZn1d_vOfUxlTlYcovD3pHkybRoGcfRdcS6YSCdw3lHhtBj7Agj7s-UXSkhRRIimXAOLs6F_A5LUIhzxp1bRUvsLg0Y-5AsZhtiGvE9QTK6GWuMONyVUF5Vzz0OxV0c9_Pq5-dPPy6_1tffvlxdfryurWj1XHvNOislY9KDln4rkVulWqUadKIB4Ei3SjoQHrnvGim1UB6aDlpOGbUNnFdXB26X8MZMOYyY70zCYO6FlHuDeel5cEY63yKTLXDQgiFTEjVDBYpvvaNdt7A-HFjTfrvMyLr1zcMT6NObGHamT7eGUSa0ou1CeHsk5PRr78psxlDWUWN0aV8MV1Q3ApSEJZQfQm1OpWTnH-owalYnmHsnmNUJ5uiEJenN4w4fUv7_O_wDdvi0Qg
CitedBy_id crossref_primary_10_3389_fimmu_2024_1378760
crossref_primary_10_1111_liv_15984
crossref_primary_10_1016_j_biopha_2024_116659
crossref_primary_10_3892_ijo_2023_5585
Cites_doi 10.3389/fphar.2022.894407
10.1016/j.suc.2020.02.013
10.1007/s10654-010-9491-z
10.18632/oncotarget.12810
10.7150/thno.28742
10.3390/cancers14092190
10.1136/bmj.n160
10.1016/j.molmed.2014.10.009
10.7150/thno.36276
10.1136/jitc-2020-001638
10.4143/crt.2016.066
10.1002/cncr.34552
10.1093/annonc/mdv615
10.3389/fimmu.2022.954910
10.1016/j.jhep.2019.10.009
10.1186/s12885-019-6276-y
10.2217/fon-2020-0683
10.1080/2162402X.2021.1933332
10.1016/j.canlet.2019.02.022
10.1186/s12967-022-03342-6
10.1159/000514404
10.1007/s11934-019-0866-8
10.1593/tlo.13256
10.3389/fmed.2020.00368
10.3389/fimmu.2021.799822
10.1007/s12022-020-09630-5
10.1038/s41379-020-00702-9
10.1136/bmj.n71
10.3390/jpm12071073
10.1111/cpr.12571
10.1002/path.5280
10.1016/j.tcb.2018.08.005
10.1371/journal.pone.0182692
10.1038/bjc.2015.101
10.1016/j.jtho.2016.04.014
10.1136/bmj.327.7414.557
10.12998/wjcc.v10.i27.9743
10.2147/OTT.S250454
10.1186/1745-6215-8-16
10.1097/CJI.0000000000000187
10.1007/s00251-017-1015-5
10.21037/tcr.2020.04.11
10.18632/oncotarget.15532
10.1186/s12957-020-02082-5
10.2147/OTT.S288982
10.1038/s41416-021-01569-6
10.7150/jca.46158
10.1016/j.immuni.2018.03.014
10.3389/fonc.2018.00386
ContentType Journal Article
Copyright Copyright © 2023 Xian, Ren, Bie and Xu.
Copyright © 2023 Xian, Ren, Bie and Xu 2023 Xian, Ren, Bie and Xu
Copyright_xml – notice: Copyright © 2023 Xian, Ren, Bie and Xu.
– notice: Copyright © 2023 Xian, Ren, Bie and Xu 2023 Xian, Ren, Bie and Xu
DBID CGR
CUY
CVF
ECM
EIF
NPM
AAYXX
CITATION
7X8
5PM
DOA
DOI 10.3389/fimmu.2023.1119168
DatabaseName Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
CrossRef
MEDLINE - Academic
PubMed Central (Full Participant titles)
Directory of Open Access Journals
DatabaseTitle MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
CrossRef
MEDLINE - Academic
DatabaseTitleList MEDLINE - Academic
CrossRef

MEDLINE
Database_xml – sequence: 1
  dbid: DOA
  name: Directory of Open Access Journals
  url: https://www.doaj.org/
  sourceTypes: Open Website
– sequence: 2
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 3
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Biology
EISSN 1664-3224
EndPage 1119168
ExternalDocumentID oai_doaj_org_article_7ef6a176323941a187a91a8382bfe0dd
10_3389_fimmu_2023_1119168
37138876
Genre Research Support, Non-U.S. Gov't
Meta-Analysis
Systematic Review
GrantInformation_xml – fundername: ;
GroupedDBID 53G
5VS
9T4
AAFWJ
AAKDD
ACGFO
ACGFS
ACXDI
ADBBV
ADRAZ
AENEX
AFPKN
ALMA_UNASSIGNED_HOLDINGS
AOIJS
BAWUL
BCNDV
CGR
CUY
CVF
DIK
EBS
ECM
EIF
EMOBN
GROUPED_DOAJ
GX1
HYE
IAO
IEA
IHR
IHW
IPNFZ
KQ8
M48
M~E
NPM
OK1
PGMZT
RIG
RNS
RPM
AAYXX
CITATION
7X8
5PM
ID FETCH-LOGICAL-c469t-f91dc77117f397fb7a2c886885ae45332a0b87e34fa2fd577948f35d362010c53
IEDL.DBID RPM
ISSN 1664-3224
IngestDate Tue Oct 22 15:14:08 EDT 2024
Tue Sep 17 21:31:04 EDT 2024
Fri Oct 25 03:26:29 EDT 2024
Thu Sep 26 18:58:15 EDT 2024
Sat Sep 28 08:14:34 EDT 2024
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Keywords meta-analysis
intrahepatic carcinoma
prognostic value
programmed cell death ligand 1 (PDL1)
programmed cell death 1 (PD-1)
Language English
License Copyright © 2023 Xian, Ren, Bie and Xu.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c469t-f91dc77117f397fb7a2c886885ae45332a0b87e34fa2fd577948f35d362010c53
Notes ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-1
content type line 23
ObjectType-Undefined-3
Reviewed by: Albino Eccher, Integrated University Hospital Verona, Italy; Bing Feng, Pennington Biomedical Research Center, United States; Jian Zhou, Chinese Academy of Sciences (CAS), China
Edited by: Hongda Liu, Nanjing Medical University, China
This article was submitted to Cancer Immunity and Immunotherapy, a section of the journal Frontiers in Immunology
OpenAccessLink https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10149806/
PMID 37138876
PQID 2809543873
PQPubID 23479
PageCount 1
ParticipantIDs doaj_primary_oai_doaj_org_article_7ef6a176323941a187a91a8382bfe0dd
pubmedcentral_primary_oai_pubmedcentral_nih_gov_10149806
proquest_miscellaneous_2809543873
crossref_primary_10_3389_fimmu_2023_1119168
pubmed_primary_37138876
PublicationCentury 2000
PublicationDate 2023-04-17
PublicationDateYYYYMMDD 2023-04-17
PublicationDate_xml – month: 04
  year: 2023
  text: 2023-04-17
  day: 17
PublicationDecade 2020
PublicationPlace Switzerland
PublicationPlace_xml – name: Switzerland
PublicationTitle Frontiers in immunology
PublicationTitleAlternate Front Immunol
PublicationYear 2023
Publisher Frontiers Media S.A
Publisher_xml – name: Frontiers Media S.A
References Xiong (B25) 2020; 13
Chen (B6) 2016; 27
Stutvoet (B9) 2019; 249
Kim (B39) 2021; 99
Xie (B45) 2022; 13
Nunes-Xavier (B41) 2019; 20
Kelley (B2) 2020; 72
Gu (B18) 2017; 12
Yugawa (B37) 2021; 34
Liu (B46) 2020; 7
Mejia (B1) 2020; 100
Yu (B12) 2016; 11
Ha (B31) 2016; 7
Tao (B34) 2020; 9
Ohaegbulam (B4) 2015; 21
Wu (B23) 2021; 14
Page (B26) 2021; 372
Yin (B20) 2021; 10
Abiko (B40) 2015; 112
Zhu (B44) 2022; 10
Page (B27) 2021; 372
Huang (B14) 2017; 40
Ma (B16) 2018; 8
Zheng (B38) 2022; 129
Munari (B48) 2022; 13
Lu (B22) 2019; 9
Wang (B24) 2021; 12
Wang (B13) 2021; 17
Higgins (B30) 2003; 327
Stang (B29) 2010; 25
Lan (B32) 2022; 126
Zhao (B8) 2019; 52
Zhang (B21) 2017; 8
Tierney (B28) 2007; 8
Salmaninejad (B42) 2018; 70
Yang (B36) 2022; 20
Wei (B7) 2019; 450
Marletta (B47) 2022; 12
Tan (B33) 2022; 14
Galluzzi (B10) 2019; 29
Peng (B19) 2021; 9
Dong (B5) 2018; 8
Sun (B3) 2018; 48
Cao (B11) 2019; 19
Tian (B35) 2020; 18
Jung (B15) 2017; 49
Kang (B43) 2013; 6
Chen (B17) 2020; 11
Girolami (B49) 2020; 31
References_xml – volume: 13
  year: 2022
  ident: B45
  article-title: Lenvatinib combined with a PD-1 inhibitor as effective therapy for advanced intrahepatic cholangiocarcinoma
  publication-title: Front Pharmacol
  doi: 10.3389/fphar.2022.894407
  contributor:
    fullname: Xie
– volume: 100
  year: 2020
  ident: B1
  article-title: Primary liver cancers: intrahepatic cholangiocarcinoma and hepatocellular carcinoma
  publication-title: Surg Clin North Am
  doi: 10.1016/j.suc.2020.02.013
  contributor:
    fullname: Mejia
– volume: 25
  year: 2010
  ident: B29
  article-title: Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses
  publication-title: Eur J Epidemiol
  doi: 10.1007/s10654-010-9491-z
  contributor:
    fullname: Stang
– volume: 7
  year: 2016
  ident: B31
  article-title: Soluble programmed death-ligand 1 (sPDL1) and neutrophil-to-lymphocyte ratio (NLR) predicts survival in advanced biliary tract cancer patients treated with palliative chemotherapy
  publication-title: Oncotarget
  doi: 10.18632/oncotarget.12810
  contributor:
    fullname: Ha
– volume: 8
  year: 2018
  ident: B16
  article-title: Clinical significance of PD-1/PD-Ls gene amplification and overexpression in patients with hepatocellular carcinoma
  publication-title: Theranostics
  doi: 10.7150/thno.28742
  contributor:
    fullname: Ma
– volume: 14
  year: 2022
  ident: B33
  article-title: PD-1+T-Cells correlate with nerve fiber density as a prognostic biomarker in patients with resected perihilar cholangiocarcinoma
  publication-title: Cancers
  doi: 10.3390/cancers14092190
  contributor:
    fullname: Tan
– volume: 372
  year: 2021
  ident: B26
  article-title: PRISMA 2020 explanation and elaboration: updated guidance and exemplars for reporting systematic reviews
  publication-title: BMJ
  doi: 10.1136/bmj.n160
  contributor:
    fullname: Page
– volume: 21
  start-page: 24
  year: 2015
  ident: B4
  article-title: Human cancer immunotherapy with antibodies to the PD-1 and PD-L1 pathway
  publication-title: Trends Mol Med
  doi: 10.1016/j.molmed.2014.10.009
  contributor:
    fullname: Ohaegbulam
– volume: 9
  year: 2019
  ident: B22
  article-title: Distinct PD-L1/PD1 profiles and clinical implications in intrahepatic cholangiocarcinoma patients with different risk factors
  publication-title: Theranostics
  doi: 10.7150/thno.36276
  contributor:
    fullname: Lu
– volume: 9
  start-page: e001638
  year: 2021
  ident: B19
  article-title: CMTM6 and PD-L1 coexpression is associated with an active immune microenvironment and a favorable prognosis in colorectal cancer
  publication-title: J For Immunotherapy Cancer
  doi: 10.1136/jitc-2020-001638
  contributor:
    fullname: Peng
– volume: 49
  year: 2017
  ident: B15
  article-title: Overexpression of PD-L1 and PD-L2 is associated with poor prognosis in patients with hepatocellular carcinoma
  publication-title: Cancer Res Treat
  doi: 10.4143/crt.2016.066
  contributor:
    fullname: Jung
– volume: 129
  year: 2022
  ident: B38
  article-title: The clinicopathological significance and relapse predictive role of tumor microenvironment of intrahepatic cholangiocarcinoma after radical surgery
  publication-title: Cancer
  doi: 10.1002/cncr.34552
  contributor:
    fullname: Zheng
– volume: 27
  year: 2016
  ident: B6
  article-title: Regulation of PD-L1: a novel role of pro-survival signalling in cancer
  publication-title: Ann Oncol
  doi: 10.1093/annonc/mdv615
  contributor:
    fullname: Chen
– volume: 13
  year: 2022
  ident: B48
  article-title: Comparison of three validated PD-L1 immunohistochemical assays in urothelial carcinoma of the bladder: interchangeability and issues related to patient selection
  publication-title: Front In Immunol
  doi: 10.3389/fimmu.2022.954910
  contributor:
    fullname: Munari
– volume: 72
  year: 2020
  ident: B2
  article-title: Systemic therapies for intrahepatic cholangiocarcinoma
  publication-title: J Hepatol
  doi: 10.1016/j.jhep.2019.10.009
  contributor:
    fullname: Kelley
– volume: 19
  start-page: 1022
  year: 2019
  ident: B11
  article-title: Expression and clinical significance of PD-L1 and BRAF expression in nasopharyngeal carcinoma
  publication-title: BMC Cancer
  doi: 10.1186/s12885-019-6276-y
  contributor:
    fullname: Cao
– volume: 17
  year: 2021
  ident: B13
  article-title: Expression and analysis of PD-L1 in peripheral blood circulating tumor cells of lung cancer
  publication-title: Future Oncol
  doi: 10.2217/fon-2020-0683
  contributor:
    fullname: Wang
– volume: 10
  year: 2021
  ident: B20
  article-title: Development of a novel gene signature to predict prognosis and response to PD-1 blockade in clear cell renal cell carcinoma
  publication-title: Oncoimmunology
  doi: 10.1080/2162402X.2021.1933332
  contributor:
    fullname: Yin
– volume: 450
  year: 2019
  ident: B7
  article-title: PD-L1 promotes colorectal cancer stem cell expansion by activating HMGA1-dependent signaling pathways
  publication-title: Cancer Lett
  doi: 10.1016/j.canlet.2019.02.022
  contributor:
    fullname: Wei
– volume: 20
  start-page: 140
  year: 2022
  ident: B36
  article-title: SIRPα and PD1 expression on tumor-associated macrophage predict prognosis of intrahepatic cholangiocarcinoma
  publication-title: J Trans Med
  doi: 10.1186/s12967-022-03342-6
  contributor:
    fullname: Yang
– volume: 99
  year: 2021
  ident: B39
  article-title: Programmed death ligand 1 expression as a prognostic marker in patients with advanced biliary tract cancer
  publication-title: Oncology
  doi: 10.1159/000514404
  contributor:
    fullname: Kim
– volume: 20
  year: 2019
  ident: B41
  article-title: A critical insight into the clinical translation of PD-1/PD-L1 blockade therapy in clear cell renal cell carcinoma
  publication-title: Curr Urol Rep
  doi: 10.1007/s11934-019-0866-8
  contributor:
    fullname: Nunes-Xavier
– volume: 6
  year: 2013
  ident: B43
  article-title: Tumor-infiltrating PD1-positive lymphocytes and FoxP3-positive regulatory T cells predict distant metastatic relapse and survival of clear cell renal cell carcinoma
  publication-title: Trans Oncol
  doi: 10.1593/tlo.13256
  contributor:
    fullname: Kang
– volume: 7
  year: 2020
  ident: B46
  article-title: Anti-PD-1 immunotherapy and radiotherapy for stage IV intrahepatic cholangiocarcinoma: a case report
  publication-title: Front In Med
  doi: 10.3389/fmed.2020.00368
  contributor:
    fullname: Liu
– volume: 12
  year: 2021
  ident: B24
  article-title: PD-1 inhibitors plus capecitabine as maintenance therapy for advanced intrahepatic cholangiocarcinoma: a case report and review of literature
  publication-title: Front In Immunol
  doi: 10.3389/fimmu.2021.799822
  contributor:
    fullname: Wang
– volume: 31
  start-page: 291
  year: 2020
  ident: B49
  article-title: Programmed death-ligand 1 (PD-L1) is a potential biomarker of disease-free survival in papillary thyroid carcinoma: a systematic review and meta-analysis of PD-L1 immunoexpression in follicular epithelial derived thyroid carcinoma
  publication-title: Endocr Pathol
  doi: 10.1007/s12022-020-09630-5
  contributor:
    fullname: Girolami
– volume: 34
  start-page: 798
  year: 2021
  ident: B37
  article-title: Prognostic impact of tumor microvessels in intrahepatic cholangiocarcinoma: association with tumor-infiltrating lymphocytes
  publication-title: Modern Pathol
  doi: 10.1038/s41379-020-00702-9
  contributor:
    fullname: Yugawa
– volume: 372
  year: 2021
  ident: B27
  article-title: The PRISMA 2020 statement: an updated guideline for reporting systematic reviews
  publication-title: BMJ
  doi: 10.1136/bmj.n71
  contributor:
    fullname: Page
– volume: 12
  year: 2022
  ident: B47
  article-title: Atlas of PD-L1 for pathologists: indications, scores, diagnostic platforms and reporting systems
  publication-title: J Pers Med
  doi: 10.3390/jpm12071073
  contributor:
    fullname: Marletta
– volume: 52
  year: 2019
  ident: B8
  article-title: PD-1/PD-L1 blockade rescue exhausted CD8+ T cells in gastrointestinal stromal tumours via the PI3K/Akt/mTOR signalling pathway
  publication-title: Cell Prolif
  doi: 10.1111/cpr.12571
  contributor:
    fullname: Zhao
– volume: 249
  start-page: 52
  year: 2019
  ident: B9
  article-title: Terwisscha van scheltinga AG, et al. MAPK pathway activity plays a key role in PD-L1 expression of lung adenocarcinoma cells
  publication-title: J Pathol
  doi: 10.1002/path.5280
  contributor:
    fullname: Stutvoet
– volume: 29
  start-page: 44
  year: 2019
  ident: B10
  article-title: WNT signaling in cancer immunosurveillance
  publication-title: Trends Cell Biol
  doi: 10.1016/j.tcb.2018.08.005
  contributor:
    fullname: Galluzzi
– volume: 12
  year: 2017
  ident: B18
  article-title: PD-L1 and gastric cancer prognosis: a systematic review and meta-analysis
  publication-title: PloS One
  doi: 10.1371/journal.pone.0182692
  contributor:
    fullname: Gu
– volume: 112
  year: 2015
  ident: B40
  article-title: IFN-γ from lymphocytes induces PD-L1 expression and promotes progression of ovarian cancer
  publication-title: Br J Cancer
  doi: 10.1038/bjc.2015.101
  contributor:
    fullname: Abiko
– volume: 11
  year: 2016
  ident: B12
  article-title: PD-L1 expression in lung cancer
  publication-title: J Thorac Oncol
  doi: 10.1016/j.jtho.2016.04.014
  contributor:
    fullname: Yu
– volume: 327
  year: 2003
  ident: B30
  article-title: Measuring inconsistency in meta-analyses
  publication-title: BMJ
  doi: 10.1136/bmj.327.7414.557
  contributor:
    fullname: Higgins
– volume: 10
  year: 2022
  ident: B44
  article-title: Successful treatment of stage IIIB intrahepatic cholangiocarcinoma using neoadjuvant therapy with the PD-1 inhibitor camrelizumab: a case report
  publication-title: World J Clin cases
  doi: 10.12998/wjcc.v10.i27.9743
  contributor:
    fullname: Zhu
– volume: 13
  year: 2020
  ident: B25
  article-title: Olaparib and pembrolizumab treatment for -mutated and PD-L1-Positive intrahepatic cholangiocarcinoma recurrence and metastasis: a case report
  publication-title: OncoTargets Ther
  doi: 10.2147/OTT.S250454
  contributor:
    fullname: Xiong
– volume: 8
  start-page: 16
  year: 2007
  ident: B28
  article-title: Practical methods for incorporating summary time-to-event data into meta-analysis
  publication-title: Trials
  doi: 10.1186/1745-6215-8-16
  contributor:
    fullname: Tierney
– volume: 40
  year: 2017
  ident: B14
  article-title: Relationship between PD-L1 expression and CD8+ T-cell immune responses in hepatocellular carcinoma
  publication-title: J Immunother
  doi: 10.1097/CJI.0000000000000187
  contributor:
    fullname: Huang
– volume: 70
  start-page: 73
  year: 2018
  ident: B42
  article-title: PD-1 and cancer: molecular mechanisms and polymorphisms
  publication-title: Immunogenetics
  doi: 10.1007/s00251-017-1015-5
  contributor:
    fullname: Salmaninejad
– volume: 9
  year: 2020
  ident: B34
  article-title: Clinicopathological and prognostic implications of vessels encapsulate tumor clusters with PD-L1 in intrahepatic cholangiocarcinoma patients
  publication-title: Trans Cancer Res
  doi: 10.21037/tcr.2020.04.11
  contributor:
    fullname: Tao
– volume: 8
  year: 2017
  ident: B21
  article-title: Expression of PD-L1 and prognosis in breast cancer: a meta-analysis
  publication-title: Oncotarget
  doi: 10.18632/oncotarget.15532
  contributor:
    fullname: Zhang
– volume: 18
  start-page: 303
  year: 2020
  ident: B35
  article-title: PD-1/PD-L1 expression profiles within intrahepatic cholangiocarcinoma predict clinical outcome
  publication-title: World J Surg Oncol
  doi: 10.1186/s12957-020-02082-5
  contributor:
    fullname: Tian
– volume: 14
  start-page: 39
  year: 2021
  ident: B23
  article-title: Clinicopathological and prognostic significance of immunoscore and PD-L1 in intrahepatic cholangiocarcinoma
  publication-title: OncoTargets Ther
  doi: 10.2147/OTT.S288982
  contributor:
    fullname: Wu
– volume: 126
  year: 2022
  ident: B32
  article-title: Cancer-associated fibroblast senescence and its relation with tumour-infiltrating lymphocytes and PD-L1 expressions in intrahepatic cholangiocarcinoma
  publication-title: Br J Cancer
  doi: 10.1038/s41416-021-01569-6
  contributor:
    fullname: Lan
– volume: 11
  year: 2020
  ident: B17
  article-title: Correlation of PD-L1 and SOCS3 Co-expression with the prognosis of hepatocellular carcinoma patients
  publication-title: J Cancer
  doi: 10.7150/jca.46158
  contributor:
    fullname: Chen
– volume: 48
  year: 2018
  ident: B3
  article-title: Regulation and function of the PD-L1 checkpoint
  publication-title: Immunity
  doi: 10.1016/j.immuni.2018.03.014
  contributor:
    fullname: Sun
– volume: 8
  year: 2018
  ident: B5
  article-title: Tumor-intrinsic PD-L1 signaling in cancer initiation, development and treatment: beyond immune evasion
  publication-title: Front In Oncol
  doi: 10.3389/fonc.2018.00386
  contributor:
    fullname: Dong
SSID ssj0000493335
Score 2.4043643
SecondaryResourceType review_article
Snippet Programmed cell death ligand 1 (PD-L1) is highly expressed in intrahepatic cholangiocarcinoma (ICC) tissues. But there is still a dispute over the prognostic...
Background Programmed cell death ligand 1 (PD-L1) is highly expressed in intrahepatic cholangiocarcinoma (ICC) tissues. But there is still a dispute over the...
BackgroundProgrammed cell death ligand 1 (PD-L1) is highly expressed in intrahepatic cholangiocarcinoma (ICC) tissues. But there is still a dispute over the...
SourceID doaj
pubmedcentral
proquest
crossref
pubmed
SourceType Open Website
Open Access Repository
Aggregation Database
Index Database
StartPage 1119168
SubjectTerms B7-H1 Antigen - metabolism
Bile Duct Neoplasms
Bile Ducts, Intrahepatic - metabolism
Cholangiocarcinoma
Humans
Immunology
intrahepatic carcinoma
Ligands
meta-analysis
Neoplasm Recurrence, Local
Prognosis
prognostic value
programmed cell death 1 (PD-1)
programmed cell death ligand 1 (PDL1)
SummonAdditionalLinks – databaseName: Directory of Open Access Journals
  dbid: DOA
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1La9wwEBYhEMiltE0f2xcq9FbcWJatR25JaAiFlhwSyE2MbU3i0pXLZhfaU_56Z2wn7JZCL7nKxh7PN9J8I49mhPiQRx1zRE7F8S4rq7rNaq901pSQg7FYueGg8Ndv5vSi_HJZXa61-uKcsLE88Ki4fRvRgKJZwD28FShnwStw2hU1xrxth9U392vB1PeR92qtq_GUDEVhfh-7-Xz1iZuF8ypBpMhteKKhYP-_WObfyZJr3ufksXg00UZ5OIr7RGzF9FTsjI0kf--J27NFzxlzdFVy-e4oe5RT6hU9VPL2vGyZ7ckf3RWkVioZf005sEl2SU71VW8kb8zSAAlxHXmwkUP4m6468nqLpkv9HA4kyHlcQgZTSZNn4uLk8_nxaTa1ViAQjF9m6FXbWKuURSIkWFsoGueMcxXEkhhgAXntbNQlQoFtZWnWOtRVS-6OArim0s_FdupTfCkk74PohiApbF0adKDRGIAGsabv8nomPt6pOfwcK2gEijwYlDCAEhiUMIEyE0eMxP2dXP16GCCbCJNNhP_ZxEy8v8Mx0GxhHUOK_eomFI4oZamdJbFejLjev0pTvE5LrpkJt4H4hiybV1J3PVTk5obH3uXm1UNI_1rsskb4l5Wyb8T2crGKb4n5LOt3g5H_AYGdBCo
  priority: 102
  providerName: Directory of Open Access Journals
– databaseName: Scholars Portal Journals: Open Access
  dbid: M48
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV3daxQxEA-1Ivgiav04rSVC32TrZrObZAUptliKoPjgQd_C7G5y3dLL6t4dtE_-687s5oonLfia7Ecyv53Mb7KTGcb2Uydd6j2F4pQmyYuqSapSyKTOIQWlfWGGg8Jfv6nTaf7lrDjbYutyR1GAi1tdO6onNe0vD65-XR-iwn8kjxPt7XvfzuerA6oDTgsA8h1zj93PcvTUKZQv0v2LkQ1LKYvx7Mwdt27YpyGN_23c898Qyr9s0slj9iiSSf5pRP8J23LhKXswlpe83mG_v_cdxdFhL6ek3o53nseALHwop0173hAH5JftDELDBXdXMTI28DbwmHV1wWm7FhtwEOeOGms-SC7MWrSFfd2Gbg4fOPC5W0ICMdHJMzY9-fzj-DSJBRcQGlUuE1-KptZaCO2RpvhKQ1Ybo4wpwOXICzNIK6OdzD1kvik06rLxsmjQCKJbVxfyOdsOXXAvGafdEVkLMJmucuUNSK8UQO19hfMq5YS9W4vZ_hzzalj0RwgUO4BiCRQbQZmwI0Li5krKiT00dP3MRhWz2nkFAtdLqvYuQBgNJQ5AmqzyLm2aCXu7xtGiDpGMIbhutbCZQaKZS6NxWC9GXG9eJdGLx4VYTZjZQHxjLJs9oT0f8nRTGeTSpOrVf7z4NXtIE6b_VELvsu1lv3JvkO4sq73hG_4DYLICEw
  priority: 102
  providerName: Scholars Portal
Title Prognostic value of programmed cell death ligand 1 expression in patients with intrahepatic cholangiocarcinoma: a meta-analysis
URI https://www.ncbi.nlm.nih.gov/pubmed/37138876
https://search.proquest.com/docview/2809543873
https://pubmed.ncbi.nlm.nih.gov/PMC10149806
https://doaj.org/article/7ef6a176323941a187a91a8382bfe0dd
Volume 14
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9QwELbaSkhcEG-WR2Ukbii7cZzYDjeoKBXSoh6otLdo4tjboMaptrsSnPjrzDhJ1UWcuPhg5zHx58c3k_EMY-9SJ13qPbnilCbJi7pJ6lLIxOaQgtK-MPGg8PKbOrvIv66K1QFT01mY6LRv63Yerrp5aC-jb-V1ZxeTn9jifHlC-WVLk6rFITvEEXpHR_8xcF4pZTGckEENrFz4tut2c0oUTisEEiKztwvFYP3_Yph_O0re2XlOH7IHI2XkHwfRHrEDFx6ze0MSyV9P2O_zTU_ectjKKXS3473no9sVPpSTaZ43xPT4VbuG0HDB3c_R_zXwNvAxtuoNJ6MsVqAQl44qLY-qb1i3uONtbBv6Dj5w4J3bQgJjOJOn7OL08_eTs2RMq4AAqHKb-FI0VmshtEcy4msNmTVGGVOAy5H9ZZDWRjuZe8h8U2icscbLosGtDpU3W8hn7Cj0wb1gnGwg0gowma5z5Q1IrxSA9b7G7yrljL2furm6HqJnVKh1EChVBKUiUKoRlBn7REjcXkmRr2NFv1lXI_6Vdl6BwFWRcroLEEZDiQJIk9XepU0zY28nHCucKdTHEFy_u6kyg3Qyl0ajWM8HXG9fJVFXx-VWzZjZQ3xPlv0WHJwxGvc0GF_-_62v2H3qB_pJJfRrdrTd7Nwb5Drb-jjaCLD8shJYLnNzHAf7H6b5Bkk
link.rule.ids 230,315,730,783,787,867,888,2109,24330,27936,27937,53804,53806
linkProvider National Library of Medicine
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9QwELZKEYIL78fyNBI3lGwcJ7bTW1tRLdCtemhFb5bt2NtA41TbrARc-Osd51F1Ky5wtRNl7BmPv3E-zyD0IbHUJs4FKk4hoizXZaQLQiOTqUQx7nLRXRSeH7DZcfblJD_ZQGy8C9OR9o2uYn9Wx7467biV57WZjjyx6eF8N9SXLUTCprfQbViwSXYtSv_eo15Kad7fkYEYrJi6qq5XcSgVHnwEQCKxtg916fr_hjFvUiWv7T17D9C3UeqecvIjXrU6Nr9vJHT892E9RPcHOIq3-_5HaMP6x-hOX6Dy1xP053DZBCYe9OKQFtzixuGB0gXi4nDsj8uAIvFZtVC-xATbnwO31uPK4yFv6wUOB77QAMM7taHR4C6s9osKdtOlqXxTqy2scG1bFakhVcpTdLz36Wh3Fg0lG0C5rGgjV5DScE4IdwB0nOYqNUIwIXJlM0CWqUq04JZmTqWuzDl4A-FoXsI2CoGhyekztOkbb18gHM5XqCFKpFxnzAlFHWNKGec0jKugE_RxVKA87zNzSIhogrplp24Z1C0HdU_QTtDx1ZMhq3bX0CwXclCC5NYxRcDjhnrxRBHBVQECUJFqZ5OynKD3o4VIWIVhjpW3zepCpgKgakYFB7Ge9xZz9SnKCQVXziZIrNnSmizrPWAhXabv0SJe_v-r79Dd2dF8X-5_Pvj6Ct0LcxJ-hhH-Gm22y5V9A5iq1W-7BXQJ-oElrQ
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9QwELagCMSFN3R5GokbyiaOE9vhBoVVebTaA5UqcYhsx96GNs5qNysBF_4648SpuhWnXu1EGXvG42-czzMIvUkMNYm1nopTiCjLVRWpgtBIZzKRjNtc9BeFDw7Z_lH25Tg_DqzKdaBVOq3qqTtrpq4-6bmVy0bHI08snh_s-fqyhUhYvKxsfB3dgEWbsAuR-s8B-VJK8-GeDMRhRWzrptlMfblw7ycAFomtvahP2f8_nHmZLnlh_5ndRT9GyQfayel006mp_nMpqePVhnYP3QmwFL8fnrmPrhn3AN0cClX-foj-zletZ-RBL_bpwQ1uLQ7ULhAZ--N_XHk0ic_qhXQVJtj8Chxbh2uHQ_7WNfYHv9AAQzwxvlHjPrx2ixp21ZWuXdvId1jixnQykiFlyiN0NPv0fW8_CqUbQMms6CJbkEpzTgi3AHis4jLVQjAhcmkyQJipTJTghmZWprbKOXgFYWlewXYKAaLO6WO041pndhH25yxUEylSrjJmhaSWMSm1tQrGVdAJejsqsVwOGTpKiGy8yste5aVXeRlUPkEfvJ7Pn_TZtfuGdrUogyJKbiyTBDyvrxtPJBFcFiAAFamyJqmqCXo9WkkJq9HPsXSm3azLVABkzajgINaTwWrOP0U5oeDS2QSJLXvakmW7B6ykz_g9WsXTq7_6Ct2af5yV3z4ffn2Gbvsp8f_ECH-OdrrVxrwAaNWpl_0a-gcIASgt
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Prognostic+value+of+programmed+cell+death+ligand+1+expression+in+patients+with+intrahepatic+cholangiocarcinoma%3A+a+meta-analysis&rft.jtitle=Frontiers+in+immunology&rft.au=Xian%2C+Feng&rft.au=Ren%2C+Dacheng&rft.au=Bie%2C+Jun&rft.au=Xu%2C+Guohui&rft.date=2023-04-17&rft.eissn=1664-3224&rft.volume=14&rft.spage=1119168&rft.epage=1119168&rft_id=info:doi/10.3389%2Ffimmu.2023.1119168&rft.externalDBID=NO_FULL_TEXT
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1664-3224&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1664-3224&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1664-3224&client=summon